ConductScience.org, home

Paper36712142

Steroid-Refractory Autoimmune Myocarditis after Pembrolizumab Therapy: Failure of Equine Anti-Thymocyte Globulin to Prevent Heart Failure.

Baclig NV and 7 others. J Clin Case Rep, 2019. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Steroid-Refractory Autoimmune Myocarditis after Pembrolizumab Therapy: Failure of Equine Anti-Thymocyte Globulin to Prevent Heart Failure. Papers, record 36712142. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36712142

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Steroid-Refractory Autoimmune Myocarditis after Pembrolizumab Therapy: Failure of Equine Anti-Thymocyte Globulin to Prevent Heart Failure.
PubMed
Journal
J Clin Case Rep
PubMed
Year
2019
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.24
iCite
Revised in PubMed
2025-05-30
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Baclig NVN V
2Ngo CC
3Yeh ACA C
4Chung SHS H
5Cheng AA
6Grim JJ
7Graf SAS A
8Yang KCK C

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
VA999999Intramural VAUnited StatesPubMed

Source PubMed

Download CSV of grants

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129567210Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.J Am Coll Cardiol2018https://conductscience.org/library/papers/29567210PubMed
230191849Immune checkpoint inhibitors and cardiovascular toxicity.Lancet Oncol2018https://conductscience.org/library/papers/30191849PubMed
327141885Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.Nat Rev Clin Oncol2016https://conductscience.org/library/papers/27141885PubMed
428833116Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab.J Forensic Sci2018https://conductscience.org/library/papers/28833116PubMed
528797029Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.Br J Cancer2017https://conductscience.org/library/papers/28797029PubMed
626981243Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.J Immunother Cancer2016https://conductscience.org/library/papers/26981243PubMed
728220466Cardiovascular Toxicities Associated with Cancer Immunotherapies.Curr Cardiol Rep2017https://conductscience.org/library/papers/28220466PubMed
827532025Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.J Immunother Cancer2016https://conductscience.org/library/papers/27532025PubMed
925901283Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.J Immunother Cancer2015https://conductscience.org/library/papers/25901283PubMed
1029802220Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.Oncologist2018https://conductscience.org/library/papers/29802220PubMed
1129104763Cardiotoxicity of immune checkpoint inhibitors.ESMO Open2017https://conductscience.org/library/papers/29104763PubMed
1229802219Immune Checkpoint Inhibitor-Associated Myocarditis.Oncologist2018https://conductscience.org/library/papers/29802219PubMed
1327806233Fulminant Myocarditis with Combination Immune Checkpoint Blockade.N Engl J Med2016https://conductscience.org/library/papers/27806233PubMed
1527084345Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.Eur J Cancer2016https://conductscience.org/library/papers/27084345PubMed
1629567824Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.Oncologist2018https://conductscience.org/library/papers/29567824PubMed
1722614989Management of immune-related adverse events and kinetics of response with ipilimumab.J Clin Oncol2012https://conductscience.org/library/papers/22614989PubMed
1829965858Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.J Immunother2018https://conductscience.org/library/papers/29965858PubMed
1929126352Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.Clin Toxicol (Phila)2018https://conductscience.org/library/papers/29126352PubMed
2029077601Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy.J Immunother2018https://conductscience.org/library/papers/29077601PubMed

Download CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42148146Case Report: Long-term survival in advanced PD-L1-high squamous cell lung cancer following severe immune-related cardiotoxicity.Front Immunol2026https://conductscience.org/library/papers/42148146PubMed
40178703Updates in Diagnosis and Treatment of Immune Checkpoint Inhibitor Myocarditis.Curr Cardiol Rep2025https://conductscience.org/library/papers/40178703PubMed
39263485Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review.Cardiovasc Diagn Ther2024https://conductscience.org/library/papers/39263485PubMed
39256296Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review.Cardiovasc Toxicol2024https://conductscience.org/library/papers/39256296PubMed
38233099Corticosteroid-resistant immune-related adverse events: a systematic review.J Immunother Cancer2024https://conductscience.org/library/papers/38233099PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36712142

GET https://conductscience.org/api/papers/v1/36712142/authors